For hospitalized patients with COVIDâ€19 who have evidence of pneumonia, we suggest hydroxychloroquine (or chloroquine) on a caseâ€byâ€case basis. Requirements include all of the following: a) shared decisionâ€making in which the patient is informed about the possible benefits and potential side effects, b) collection of data in a manner that enables studies that use valid methods for causal inference and control of confounders for the purpose of interim assessment, c) the patientÂ’s clinical condition is sufficiently severe to warrant investigational therapy, and d) there is not a shortage of drug supply. 73% for intervention, 16% no suggestion, and 11% against...